Norfloxacin versus co-trimoxazole for the treatment of upper urinary tract infections: a double blind trial. 1988

K Tungsanga, and A Chongthaleong, and N Udomsantisuk, and O A Petcharabutr, and V Sitprija, and E C Wong
Department of Medicine, Chulalongkorn Hospital Medical School, Bangkok, Thailand.

The clinical and bacteriological efficacy of norfloxacin and co-trimoxazole was compared in patients with symptomatic upper urinary tract infections (UTI). Norfloxacin 400 mg or cotrimoxazole (160 mg of trimethoprim plus 800 mg of sulphamethoxazole) were given orally b.i.d. for seven days to 94 Thai patients. Clinical and bacteriological assessments were performed before and at 5, 14 and 21 days after start of treatment. Bacteriological outcome could be evaluated in 69 patients, 35 randomized to norfloxacin and 34 to co-trimoxazole. The bacteriological cure rate assessed four to seven days after treatment was significantly higher in the norfloxacin than in the co-trimoxazole group (94.3% vs. 73.5%; p less than 0.05). Few patients in each group reported mild and transient adverse effects. We conclude that norfloxacin was well tolerated and more effective than co-trimoxazole in the treatment of upper UTI.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009643 Norfloxacin A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE. AM-0715,AM-715,MK-0366,MK-366,MK0366,MK366,Noroxin,AM 0715,AM 715,AM0715,MK 0366,MK 366
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

K Tungsanga, and A Chongthaleong, and N Udomsantisuk, and O A Petcharabutr, and V Sitprija, and E C Wong
September 1987, Urology,
K Tungsanga, and A Chongthaleong, and N Udomsantisuk, and O A Petcharabutr, and V Sitprija, and E C Wong
January 1986, Scandinavian journal of infectious diseases. Supplementum,
K Tungsanga, and A Chongthaleong, and N Udomsantisuk, and O A Petcharabutr, and V Sitprija, and E C Wong
February 1989, The British journal of clinical practice,
K Tungsanga, and A Chongthaleong, and N Udomsantisuk, and O A Petcharabutr, and V Sitprija, and E C Wong
January 1987, Scandinavian journal of infectious diseases,
K Tungsanga, and A Chongthaleong, and N Udomsantisuk, and O A Petcharabutr, and V Sitprija, and E C Wong
March 1976, British medical journal,
K Tungsanga, and A Chongthaleong, and N Udomsantisuk, and O A Petcharabutr, and V Sitprija, and E C Wong
January 1988, Scandinavian journal of infectious diseases. Supplementum,
K Tungsanga, and A Chongthaleong, and N Udomsantisuk, and O A Petcharabutr, and V Sitprija, and E C Wong
March 1993, The American journal of medicine,
K Tungsanga, and A Chongthaleong, and N Udomsantisuk, and O A Petcharabutr, and V Sitprija, and E C Wong
September 1972, Nederlands tijdschrift voor geneeskunde,
K Tungsanga, and A Chongthaleong, and N Udomsantisuk, and O A Petcharabutr, and V Sitprija, and E C Wong
January 1990, BMJ (Clinical research ed.),
K Tungsanga, and A Chongthaleong, and N Udomsantisuk, and O A Petcharabutr, and V Sitprija, and E C Wong
January 1983, Arzneimittel-Forschung,
Copied contents to your clipboard!